Search
Iovance Biotherapeutics Inc
IOVAAdd to Watchlist
14.560USD
-0.060-0.41%
Close 10-12 16:00（ET）
6.50BMarket Cap
LossP/E TTM
Iovance Biotherapeutics Inc (IOVA) Stock Price Target & Forecast
Analyst Rating
Based on 10 analysts giving stock ratings to Iovance Biotherapeutics Inc in the past month.
Buy
1 Strong Buy
7 Buy
2 Hold
0 Sell
0 Strong Sell
Target Price
13.300USD-9.03%
IOVA Analyst Recommendation Trends
In the current month, IOVA has received 7 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. IOVA average Analyst price target in the last month is 13.300.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
1
1
1
1
1
1
1
1
7
6
7
7
7
7
7
6
2
2
2
2
3
3
3
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
10
9
10
10
11
11
11
12
IOVA Analyst Rating for Peer Comparison
Updated: Oct 12, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
13
3
0
0
26
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Insmed Inc
INSM
7
18
0
0
0
25
CRISPR Therapeutics AG
CRSP
4
9
11
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Revolution Medicines Inc
RVMD
8
14
1
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
IQVIA Holdings Inc
IQV
8
11
3
0
0
22
Biontech SE
BNTX
4
13
5
0
0
22
Financial Forecasting
Based on analysts' estimates, IOVA EPS is projected to reach -0.085 in FY2026Q3, following reported EPS of -0.105 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.17
-0.15
-0.13
-0.09
-0.08
Actual
-0.18
-0.19
-0.11
--
--
Surprise
-2.77%
-26.10%
+16.42%
--
--
FAQs
What is Iovance Biotherapeutics Inc's expected revenue for the next quarter?
Iovance Biotherapeutics Inc's expected revenue is 114.44M.
What is Iovance Biotherapeutics Inc's price target?
Analysts forecast that Iovance Biotherapeutics Inc's price target is USD 13.30, with the highest forecast at USD 20.00 and the lowest forecast at USD 7.00.
How have Iovance Biotherapeutics IncIOVA's recent earnings per share performed?
The market expectation was USD -0.11, while Iovance Biotherapeutics IncIOVA's earnings per share (EPS) for the previous quarter was USD -0.19. EPS for the next quarter is expected at USD -0.09.
What is the analyst rating for Iovance Biotherapeutics Inc?
Based on the ratings of Iovance Biotherapeutics Inc's stock from 10 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.